.png){kind=icon}
.png){kind=icon}
Return
Complicated urinary tract infections: evolving definitions, clinical burden, and treatment landscape amid antimicrobial resistance
.png){kind=icon}
OA
AI
K
A
G
F
DOI：10.1080/14787210.2026.2700381.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Complicated urinary tract infection (cUTI) is a common and heterogenous infection associated with substantial morbidity, high healthcare utilization, and increasing antimicrobial resistance. Evolving definitions, increasing device use, and changing patient populations have altered its epidemiology and management. Marked variability in diagnostic criteria, clinical trial endpoints within and outside registrational settings, and treatment strategies complicates clinical decision-making and interpretation of therapeutic advances.
This review examines contemporary cUTI epidemiology, classification frameworks, and drivers of disease burden. It evaluates resistance trends and their therapeutic implications, alongside stewardship-based management strategies, including empiric antibiotic selection, intravenous-to-oral transition, treatment duration, and source control. Challenges in catheter-associated infection, recurrence, and regulatory endpoint design are discussed, together with the emerging role of novel agents targeting resistant Gram-negative pathogens.
Rising multidrug resistance and limited oral options are reshaping cUTI management, necessitating individualized, stewardship-aligned therapy guided by illness severity and local epidemiology. Current regulatory endpoints inadequately reflect patient-centered outcomes, particularly in the context of asymptomatic bacteriuria. Expanding availability of effective oral agents may enable earlier discharge and outpatient care. Integration of rapid diagnostics and risk stratification will be essential to optimize therapy, limit resistance, and improve outcomes.
Keywords:
Complicated urinary tract infection
antimicrobial resistance
ESBL-producing enterobacterales
Multidrug-resistant enterobacterales
oral step-down therapy
beta-lactam/beta-lactamase inhibitor
recurrent urinary tract infection
asymptomatic bacteriuria
Journal
E
IF:
3.8
Papers:
2.3K
Citations:
6.1K
Organization
Cited Papers